Sirodusk Tablet contains Sirolimus 1 mg, a potent mTOR inhibitor and immunosuppressant widely used in organ transplant medicine to prevent graft rejection.
This tablet works by modulating the mammalian target of rapamycin (mTOR) pathway, suppressing T-lymphocyte proliferation and reducing immune-mediated damage to transplanted organs. It is ideal for patients requiring targeted immunosuppression under strict medical supervision.
Clinically, Sirodusk Tablet is used in renal, hepatic, and cardiac transplant protocols, often in combination with calcineurin inhibitors and corticosteroids, to maintain graft survival and reduce the risk of rejection episodes.
The tablet ensures accurate dosing, consistent bioavailability, and reliable therapeutic outcomes, making it suitable for hospitals, transplant centers, specialty clinics, and pharmacies managing long-term post-transplant immunosuppressive therapy.
Common side effects include mouth ulcers, acne, diarrhea, fatigue, headache, and mild infections. Rare but serious effects include severe infections, thrombocytopenia, leukopenia, hyperlipidemia, impaired wound healing, and lung toxicity.
Sirodusk Tablet is indicated for the prevention of organ transplant rejection, particularly in renal transplant recipients, when used in combination with other immunosuppressive agents. It may also be used under specialist supervision for certain autoimmune or proliferative disorders.
Use Sirodusk Tablet strictly under medical supervision. Regular monitoring of blood counts, kidney and liver function, lipid profile, and drug levels is essential. Inform your doctor if you have active infections, liver disease, or are taking other immunosuppressive medications. Avoid live vaccines during therapy and seek immediate medical attention if persistent fever, unusual bleeding, or breathing difficulties occur.
Store in a cool, dry place below 25°C. Protect from light and moisture. Keep out of reach of children. Do not use beyond the expiry date.